If you find yourself weighing whether to hold onto, buy, or maybe even trim your position in MetLife, you are not alone. The stock finished at $81.62 most recently, which puts its short-term returns in a fairly tight range. Over the last week, MetLife dipped by just -0.5%, with a slightly positive 1.4% lift over the past month. That kind of calm might seem a bit surprising when you consider the bigger picture: the stock has surged 33.0% in the last three years, and a remarkable 144.5% in five.

The real question for investors right now is less about what MetLife stock will do next week, and more about whether it still offers compelling value after such a run. Market-watchers have pointed to shifting interest rate expectations and ongoing economic uncertainty as factors behind recent swings. Investors are sifting through these signals and trying to figure out if the current price is justified by fundamentals or swayed by short-term sentiment.

Looking at the numbers, MetLife comes through as undervalued in 5 out of 6 common valuation checks, giving it a strong value score of 5. This means it passes most of the criteria that analysts use to identify bargains, making it stand out amid a crowded field of insurers. With that in mind, let’s dig into the common valuation methods to see just how MetLife stacks up. Stay tuned, because we will explore an even more insightful way to judge its value at the end of the article.

Why MetLife is lagging behind its peers

The Excess Returns model aims to measure how much value a company can create above its cost of equity by focusing on its ability to generate returns from invested capital over time. This approach is especially relevant for financial companies like MetLife because it centers around Return on Equity (ROE) rather than future cash flows.

According to this framework, MetLife's Book Value per share stands at $41.52, with its Stable Book Value estimated at $43.74 per share based on the weighted projections of five analysts. The company’s Stable Earnings Per Share (EPS) is calculated at $6.47, as inferred from the consensus future ROE estimates of seven analysts. MetLife’s average ROE is 14.78%, which is above its cost of equity of $3.35 per share. This produces an excess return of $3.12 per share, signaling the business’s ability to generate profits beyond merely covering its cost of capital.

The bottom line from the Excess Returns valuation is clear: the model suggests an intrinsic value for MetLife that is 27.0% higher than its current share price, pointing to the stock being notably undervalued at present levels.

Result: UNDERVALUED

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for MetLife.

Our Excess Returns analysis suggests MetLife is undervalued by 27.0%. Track this in your watchlist or portfolio, or discover more undervalued stocks.

The Price-to-Earnings (PE) ratio is a widely used metric for valuing consistently profitable companies such as MetLife. It helps investors gauge how much the market is willing to pay for a dollar of current earnings, and is particularly insightful where companies have stable and visible profit streams.

However, determining what a “normal” or “fair” PE ratio should be is not one-size-fits-all. Market participants typically expect to pay a higher multiple for companies with strong earnings growth prospects or lower perceived risk. Conversely, companies facing higher risks or slower growth usually command lower PE ratios.

MetLife’s current PE ratio stands at 13.27x, comparing favorably with the insurance industry average of 14.18x and peer average of 17.73x. To go deeper, Simply Wall St calculates a proprietary “Fair Ratio” for each stock. For MetLife, the Fair Ratio is 16.94x, which reflects a blend of factors such as expected earnings growth, industry dynamics, profit margin, market capitalization, and the company’s specific risk profile.

Unlike simple peer or industry comparisons, the Fair Ratio provides a more holistic and tailored benchmark. It considers the nuances that generic averages simply overlook. This means investors get a clearer picture of what’s fair for MetLife specifically, rather than relying on broad comparisons.

Since MetLife’s current PE ratio is noticeably below its Fair Ratio, this indicates the stock is undervalued based on this metric.

Result: UNDERVALUED

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth.

Earlier we mentioned that there is an even better way to understand valuation, so let’s introduce you to Narratives, an easy, dynamic tool that guides millions of investors on Simply Wall St’s Community page.

A Narrative connects your view of MetLife’s story, including its prospects, risks, and strategy, to your expectations for future revenue, earnings, and margins. This process turns your story into a forecast and then a fair value estimate for the stock.

Rather than only relying on ratios or analyst targets, Narratives help you clearly lay out why you think a company is undervalued or overvalued based on your assumptions and track how those assumptions play out over time.

Best of all, Narratives are updated automatically as new information comes in, such as earnings results or news about MetLife, making your perspective always relevant and actionable.

For example, some MetLife investors may be extremely bullish, forecasting robust overseas growth, higher margins, and setting a fair value near $108. Others see risks from volatile underwriting or slow digital adoption and set their value closer to $72. This shows how Narratives help you compare your Fair Value to the current Price so you can make more informed decisions.

Do you think there's more to the story for MetLife? Create your own Narrative to let the Community know!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include MET.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com